Western blot analysis of zotatifin and Ipatasertib treatments in the SK-BR-3 cell line support the idea that the synergistic anti-tumor activity could be attributed to the elimination of RTK induction and reversal of PI3K/AKT feedback relief outcome. The gene discussed is PIK3CA; the disease is neoplasm.